Association of thymidylate synthase gene 3′-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Wang, Xia ^a   Wang, Yadi ^a   Wang, Yue ^a   Cheng, Jian ^a   Wang, Yanyun ^a   Ha, Minwen ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Lung adenocarcinoma; Non small cell lung cancer; Pemetrexed treatment; Thymidylate synthase; TS gene polymorphism

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; MESSENGER RNA; PEMETREXED; THYMIDYLATE SYNTHASE; TUMOR MARKER; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DNA SEQUENCE; DRUG SENSITIVITY; FATIGUE; FEMALE; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; LEUKOPENIA; LIVER INJURY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR DIFFERENTIATION; VOMITING; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; SURVIVAL;

3' UNTRANSLATED REGIONS; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE;

EID: 84872806269     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-5     Document Type: Article

References (21)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A, N Engl J Med 2011 364 947 955 10.1056/NEJMct0807960 21388312
3. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. J Clin Oncol 2008 26 3543 3551 10.1200/JCO.2007.15.0375 18506025
4. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, et al. Lung Cancer 2010 69 323 329 10.1016/j.lungcan.2009.12.002 20061047
5. Updated clinical information on multitargeted antifolates in lung cancer. Scagliotti GV, Ceppi P, Capelletto E, Novello S, Clin Lung Cancer 2009 10 Suppl 1 35 S40 19362945
6. Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival. Curtin K, Ulrich CM, Samowitz WS, Bigler J, Caan B, Potter JD, et al. Int J Cancer 2007 120 2226 2232 10.1002/ijc.22603 17290389 (Pubitemid 46555863)
7. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, et al. J Clin Oncol 2006 24 1883 1891 10.1200/JCO.2005.04.8322 16622263 (Pubitemid 46638987)
8. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD, Cancer Epidemiol Biomarkers Prev 2000 9 1381 1385 11142426 (Pubitemid 32044809)
9. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. Dotor E, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, et al. J Clin Oncol 2006 24 1603 1611 10.1200/JCO.2005.03.5253 16575011 (Pubitemid 46638784)
10. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, et al. Pharmacogenetics 2004 14 319 327 10.1097/00008571-200405000-00007 15115918 (Pubitemid 38638919)
11. Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis. Zhai X, Gao J, Hu Z, Tang J, Qin J, Wang S, et al. BMC Cancer 2006 6 138 10.1186/1471-2407-6-138 16723031 (Pubitemid 46277083)
12. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of Canada. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437
13. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). August 9, 2006
14. Expression of thymidylate synthase in human non-small cell lung cancer. Otake Y, Tanaka F, Yanagihara K, Hitomi S, Okabe H, Fukushima M, et al. Jpn J Cancer Res 1999 90 1248 1253 10.1111/j.1349-7006.1999.tb00704.x 10622537
15. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Nakagawa T, Otake Y, Yanagihara K, Miyahara R, Ishikawa S, Fukushima M, et al. Lung Cancer 2004 43 145 149 10.1016/j.lungcan.2003.09.004 14739034 (Pubitemid 38114742)
16. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, et al. Cancer 2006 107 1589 1596 10.1002/cncr.22208 16955506 (Pubitemid 44546920)
17. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Hashimoto H, Ozeki Y, Sato M, Obara K, Matsutani N, Nakagishi Y, et al. Cancer 2006 106 1595 1601 10.1002/cncr.21777 16489621
18. Polymorphism in the 3′-untranslated region of thymidylate synthase gene and sensitivity of stomach cancer to fluoropymidine-based chemotherapy. Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K, Feng JF, J Hum Genet 2006 51 155 160 10.1007/s10038-005-0339-4 16424979
19. Polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase genes and the susceptibility to esophageal and stomach cancer with smoking. Gao CM, Takezaki T, Wu JZ, Liu YT, Ding JH, Li SP, et al. Asian Pac J Cancer Prev 2004 5 133 138 15244514
20. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, et al. Health Technol Assess 2010 14 Suppl 1 47 53 21047491
21. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. Hua B, Li M, Shuhang W, et al. J Clin Oncol 2009 27 16 2653 2659 10.1200/JCO.2008.17.3930 19414683